Measuring outcomes in psoriatic arthritis

Measuring outcomes in psoriatic arthritis

Detalles Bibliográficos
Main Authors:	Ogdie, A, Coates, LC, Mease, P
Formato:	Journal article
Idioma:	English
Publicado:	Wiley 2020

Títulos similares

Classification and outcome measures for psoriatic arthritis
por: Leung, Y, et al.
Publicado: (2018)

Psoriatic arthritis: prospects for the future
por: Hackett, S, et al.
Publicado: (2022)

Classification and Outcome Measures for Psoriatic Arthritis
por: Ying Ying Leung, et al.
Publicado: (2018-09-01)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
por: Ogdie, A, et al.
Publicado: (2023)

Psoriatic arthritis
por: FitzGerald, O, et al.
Publicado: (2021)

Outcome measures in psoriatic arthritis: where next?
por: Hackett, S, et al.
Publicado: (2022)

Psoriatic arthritis: prospects for the future
por: Simon Hackett, et al.
Publicado: (2022-03-01)

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies
por: Tillett, W, et al.
Publicado: (2017)

Considerations for the definition of remission criteria in psoriatic arthritis
por: Mease, P, et al.
Publicado: (2017)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
por: Alexis Ogdie, et al.
Publicado: (2023-05-01)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
por: Helliwell, PS, et al.
Publicado: (2022)

Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative
por: Antony, A, et al.
Publicado: (2021)

How should we define disease and outcomes in axial psoriatic arthritis?
por: Coates, LC
Publicado: (2021)

Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores
por: Weinstein, SM, et al.
Publicado: (2021)

Methotrexate in psoriasis and psoriatic arthritis
por: Coates, L, et al.
Publicado: (2020)

Initiating evaluation of composite outcome measures for psoriatic arthritis: 2022 updates from the GRAPPA-OMERACT Working Group
por: Leung, Y-Y, et al.
Publicado: (2023)

Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial
por: Strand, V, et al.
Publicado: (2024)

Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis
por: Leung, YY, et al.
Publicado: (2020)

Test-retest reliability for HAQ-DI and SF-36 PF for the measurement of physical function in psoriatic arthritis
por: Leung, YY, et al.
Publicado: (2021)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
por: Gladman, DD, et al.
Publicado: (2018)

Outcomes of the 2019 GRAPPA workshop on continuous composite indices for the assessment of psoriatic arthritis and membership: Recommended next steps
por: Tillett, W, et al.
Publicado: (2020)

The GRAPPA-OMERACT Working Group: 4 prioritized domains for completing the core outcome measurement set for psoriatic arthritis 2019 updates
por: Leung, YY, et al.
Publicado: (2020)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology consensus‐based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis
por: Coates, L, et al.
Publicado: (2017)

Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Philip J. Mease, et al.
Publicado: (2024-01-01)

Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Philip J. Mease, et al.
Publicado: (2023-08-01)

The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 annual meeting: report and plan for completing the core outcome measurement set
por: Leung, Y, et al.
Publicado: (2019)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
por: Mease, PJ, et al.
Publicado: (2020)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
por: Coates, L, et al.
Publicado: (2019)

Hot topice debate: preventing psoriatic arthritis in patients with psoriasis
por: Vivekanantham, A, et al.
Publicado: (2024)

Sex-specific differences in patients with psoriatic arthritis: a systematic review
por: Coates, LC, et al.
Publicado: (2022)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
por: Soriano, ER, et al.
Publicado: (2023)

The State of the Art - Psoriatic Arthritis outcome assessment in clinical trials and daily practice
por: Day, J, et al.
Publicado: (2022)

Identification of psoriatic arthritis in patients with psoriasis
por: Coates, LC, et al.
Publicado: (2023)

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
por: Coates, L, et al.
Publicado: (2020)

Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review
por: Leung, Y-Y, et al.
Publicado: (2020)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
por: Atul Deodhar, et al.
Publicado: (2022-07-01)

Obesity and Psoriatic Arthritis: A Narrative Review
por: Anand Kumthekar, et al.
Publicado: (2020-06-01)

Is axial psoriatic arthritis the same as ankylosing spondylitis with psoriasis: a debate
por: Coates, LC, et al.
Publicado: (2023)

The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
por: Strand, V, et al.
Publicado: (2022)

Psoriatic arthritis in developing and resource-poor countries
por: Maharaj, AB, et al.
Publicado: (2020)